enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Canagliflozin - Wikipedia

   en.wikipedia.org/wiki/Canagliflozin

   Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...

3. Diabetic nephropathy - Wikipedia

   en.wikipedia.org/wiki/Diabetic_nephropathy

   Diabetic nephropathy, also known as diabetic kidney disease, [5] is the chronic loss of kidney function occurring in those with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. The triad of protein leaking into the urine (proteinuria or albuminuria ...

4. Insulin Resistance: From Symptoms to Treatment - AOL

   www.aol.com/insulin-resistance-symptoms...

   Many medications can help people at risk of diabetes manage their blood sugar. The first-line medication healthcare providers prescribe is often metformin . Other medications prescribed to help ...

5. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   It is indicated in adults for the treatment of symptomatic chronic heart failure; [13] and it is indicated in adults for the treatment of chronic kidney disease. [13] Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes.

6. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

7. Finerenone - Wikipedia

   en.wikipedia.org/wiki/Finerenone

   Finerenone, marketed under the brand name Kerendia 10 or 20 mg among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. [8]